128 related articles for article (PubMed ID: 37963444)
1. UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Caracciolo D; Polerà N; Belmonte B; Conforti F; Signorelli S; Gulino A; Staropoli N; Tuccillo FM; Bonelli P; Juli G; Grillone K; Ascrizzi S; Cirillo M; Migale L; Ballerini A; Pelizon C; Di Martino MT; Tagliaferri P; Riillo C; Tassone P
Br J Haematol; 2024 Feb; 204(2):555-560. PubMed ID: 37963444
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL).
Heini AD; Bacher U; Pabst T
Br J Haematol; 2024 Feb; 204(2):389-390. PubMed ID: 37964473
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219
[TBL] [Abstract][Full Text] [Related]
4. A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells.
Riillo C; Caracciolo D; Grillone K; Polerà N; Tuccillo FM; Bonelli P; Juli G; Ascrizzi S; Scionti F; Arbitrio M; Lopreiato M; Siciliano MA; Sestito S; Talarico G; Galea E; Galati MC; Pensabene L; Loprete G; Rossi M; Ballerini A; Gentile M; Britti D; Di Martino MT; Tagliaferri P; Tassone P
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740552
[TBL] [Abstract][Full Text] [Related]
5. A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia.
Bartels L; de Jong G; Gillissen MA; Yasuda E; Kattler V; Bru C; Fatmawati C; van Hal-van Veen SE; Cercel MG; Moiset G; Bakker AQ; van Helden PM; Villaudy J; Hazenberg MD; Spits H; Wagner K
Cancer Res; 2019 Jul; 79(13):3372-3382. PubMed ID: 31064847
[TBL] [Abstract][Full Text] [Related]
6. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis.
Ma XB; Zheng Y; Yuan HP; Jiang J; Wang YP
Hum Pathol; 2015 Apr; 46(4):593-9. PubMed ID: 25682152
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.
He M; Gao L; Zhang S; Tao L; Wang J; Yang J; Zhu M
Gastric Cancer; 2014; 17(3):431-41. PubMed ID: 24232982
[TBL] [Abstract][Full Text] [Related]
8. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.
Ueno S; Yamaguchi M; Kimura M; Odagiri H; Shiraki K; Uemoto S; Nakamura N; Zhang W; Shiku H; Kobayashi T
Int J Oncol; 2005 Nov; 27(5):1241-6. PubMed ID: 16211218
[TBL] [Abstract][Full Text] [Related]
10. An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified.
Hoffmann JC; Chisholm KM; Cherry A; Chen J; Arber DA; Natkunam Y; Warnke RA; Ohgami RS
Hum Pathol; 2016 Feb; 48():9-17. PubMed ID: 26772393
[TBL] [Abstract][Full Text] [Related]
11. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma.
Skacel M; Ross CW; Hsi ED
Histopathology; 2000 Jul; 37(1):10-8. PubMed ID: 10931213
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A; Arumov A; Schatz JH
Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
[TBL] [Abstract][Full Text] [Related]
13. De Novo Unclassifiable CD20-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge.
AbdullGaffar B; Seliem RM
Int J Surg Pathol; 2018 May; 26(3):266-270. PubMed ID: 28982264
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
15. A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
Riillo C; Polerà N; Di Martino MT; Juli G; Hokanson CA; Odineca T; Signorelli S; Grillone K; Ascrizzi S; Mancuso A; Staropoli N; Caparello B; Cerra M; Nisticò G; Tagliaferri P; Crea R; Caracciolo D; Tassone P
J Transl Med; 2023 May; 21(1):301. PubMed ID: 37143061
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q
Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Aggressive B Cell Lymphomas: Updates in 2019.
Mondello P; Nowakowski GS
Curr Hematol Malig Rep; 2020 Jun; 15(3):225-234. PubMed ID: 32372238
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas.
Zheng J; Xu J; Ma S; Sun X; Geng M; Wang L
Int J Clin Exp Pathol; 2013; 6(10):2048-55. PubMed ID: 24133582
[TBL] [Abstract][Full Text] [Related]
19. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].
Xu FP; Liu YH; Zhuang HG; Luo DL; Li L; Zhang F; Luo XL; Du X; Li WY; Chen Q
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):616-21. PubMed ID: 22177246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
